Related Experiment Video
Updated: Mar 18, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity
Adriana Cruz1, Bruna Abreu2,3, Cindy Mendes2,3
1iBB-Institute for Bioengineering and Biosciences, and Associate Laboratory i4HB-Institute for Health and Bioeconomy, Instituto Superior Técnico, Lisbon, Portugal.
Abstract:
Breast carcinoma (BC) is the most common malignancy in women, with triple-negative breast cancer (TNBC) making up 10-20% of cases. TNBC has limited targeted therapies and poor survival due to late diagnosis and metastasis. Dendrimers are precise nanostructures with a three-dimensional globular architecture designed to target the negatively charged membranes of cancer cells. This study evaluated the anticancer potential of two novel core-shell polycationic polyurea (PURE) dendrimers, PUREG4-OEI48 and PUREG4-OCEI24, targeting BC cell membranes. Both dendrimers selectively interacted with TNBC cells, inducing apoptosis, necroptosis, and ferroptosis. In vivo, they reduced tumor volume in HCC1806 xenografts, with PUREG4-OEI48 showing no toxicity, while PUREG4-OCEI24 induced mild hepatic toxicity. These results suggest PURE dendrimers are promising TNBC treatments, with further modifications needed to enhance efficacy and reduce toxicity.
Insights
Novel polyurea (PURE) dendrimers show promise for treating triple-negative breast cancer (TNBC). These nanostructures target cancer cells, induce cell death, and reduce tumor size in preclinical models with manageable toxicity.
Area of Science:
- Nanotechnology
- Oncology
- Materials Science
Background:
- Breast carcinoma (BC) is a prevalent cancer in women, with triple-negative breast cancer (TNBC) representing a significant subset.
- TNBC lacks targeted therapies and exhibits poor prognosis due to late detection and metastasis.
- Dendrimers, with their unique globular architecture, offer potential for targeted cancer therapy by interacting with cell membranes.
Purpose of the Study:
- To evaluate the anticancer efficacy of two novel polycationic polyurea (PURE) dendrimers, PUREG4-OEI48 and PUREG4-OCEI24, against breast cancer.
- To investigate the selective targeting and therapeutic mechanisms of these dendrimers on TNBC cells.
Main Methods:
- Synthesis and characterization of PUREG4-OEI48 and PUREG4-OCEI24 dendrimers.
- In vitro assessment of dendrimer interaction with TNBC cell lines, including induction of apoptosis, necroptosis, and ferroptosis.
- In vivo evaluation of dendrimer efficacy and toxicity in a mouse xenograft model (HCC1806).
Main Results:
- Both PURE dendrimers demonstrated selective interaction with TNBC cells.
- Induction of multiple cell death pathways (apoptosis, necroptosis, ferroptosis) was observed in vitro.
- In vivo studies showed significant reduction in tumor volume in HCC1806 xenografts.
- PUREG4-OEI48 exhibited no observable toxicity, while PUREG4-OCEI24 caused mild hepatic toxicity.
Conclusions:
- PURE dendrimers represent a promising therapeutic strategy for TNBC.
- Further research and modifications are warranted to optimize dendrimer efficacy and minimize potential toxicity for clinical translation.
More Related Videos
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Modified-Release Drug Delivery Systems: Site-Targeted

